Andrew X. Zhang
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Click Chemistry and Applications, Monoclonal and Polyclonal Antibodies Research, Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis
Most-Cited Works
- → Proteolysis‐targeting chimeras in drug development: A safety perspective(2020)207 cited
- → A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules(2010)161 cited
- → Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease(2012)143 cited
- → Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs(2021)131 cited
- → Chemical Control over Immune Recognition: A Class of Antibody-Recruiting Small Molecules That Target Prostate Cancer(2009)125 cited
- → CETSA beyond Soluble Targets: a Broad Application to Multipass Transmembrane Proteins(2019)91 cited
- → Chemically Synthesized Molecules with the Targeting and Effector Functions of Antibodies(2014)48 cited
- → Reprogramming Urokinase into an Antibody-Recruiting Anticancer Agent(2011)28 cited
- → Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor(2024)23 cited
- → The Vital Role of Proteomics in Characterizing Novel Protein Degraders(2021)20 cited